Challenges of neoadjuvant immunotherapy in mismatch repair-deficient/microsatellite-unstable localized colon cancer patients.

M Karoui, A Mariani, J Taieb

Abstract readReview

In one paragraph

Review in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Contrast-enhanced CT colonography in colon cancer: expanding roles in staging, surgical planning and clinical decision-making.Abdominal radiology (New York) · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

M KarouiDepartment of Digestive and Oncological Surgery, Paris Cité University, Assistance Publique Hôpitaux de Paris, European Georges Pompidou University Hospital, Paris, France. Electronic address: mehdi.karoui@aphp.fr.

A MarianiDepartment of Digestive and Oncological Surgery, Paris Cité University, Assistance Publique Hôpitaux de Paris, European Georges Pompidou University Hospital, Paris, France.

J TaiebDepartment of Digestive Oncology, Assistance Publique Hôpitaux de Paris, European Georges Pompidou University Hospital, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite cumulative evidence on the efficacy and tolerability of neoadjuvant immunotherapy in mismatch repair-deficient (dMMR) colon cancer (CC), it is still hard to draw clear recommendations on its indication in our daily clinical practice. Key clinical trials investigating neoadjuvant or adjuvant immune checkpoint inhibitors (ICIs) in dMMR non-metastatic CC were reviewed. Based on their results, we designed an algorithm in the management of dMMR CC patients. The decision to treat patients with non-metastatic dMMR CC with neoadjuvant or adjuvant ICIs is primarily based on the patient's clinical status, baseline computed tomography (CT) characteristics of the primary tumor, and the therapeutic objectives.

Indexed as

Colonic NeoplasmsDNA Mismatch RepairImmunotherapyNeoadjuvant TherapyHumansMicrosatellite Instabilitylocalized colon cancerMSI/dMMRneoadjuvant immunotherapynon-metastatic colon cancer

Identifiers

PMID41812317

DOI10.1016/j.esmoop.2026.106893

PMCPMC12995471

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.